Symposium Schedule

Morning Session

9:00-9:10 Welcome: Steve Martin; Introduction: Ellen Robey
Chair: David Raulet

9:10-9:45 MAX KRUMMEL, University of California, San Francisco
“Defining the Path from Tumor Antigens to T cell Tolerance"

9:45-10:20 BOB SCHREIBER, Washington University, St. Louis
"Cancer Immunoediting: Underlying Mechanisms and Therapeutic Implications”

10:20-10:50 BREAK (refreshments provided)

10:50-11:25 DAVID RAULET, University of California, Berkeley
"How innate mechanisms enable killer cells to detect cancer cells"

11:25-12:00 PHIL GREENBERG, University of Washington, Seattle
"Engineering cells for tumor therapy: Getting T cells all dressed up and ready to kill"

12:00-1:30 LUNCH BREAK

Afternoon Session

1:30-1:40 Chair: Mark Schlissel

1:40-2:15 JIM ALLISON, Memorial Sloan-¬‐Kettering Cancer Center, NY, New York
"Immune Checkpoint Blockade: New Insights and Opportunities"

2:15-2:50 PADMANEE SHARMA, University of Texas MD Anderson Cancer Center, Houston, Texas
"Investigating the ICOS/ICOSL pathway as a target to improve anti-¬‐CTLA-¬ ‐4 therapy"

2:50-3:20 BREAK (refreshments provided)

3:20-3:55 JEDD WOLCHOK, Memorial Sloan-‐Kettering Cancer Center, NY, New York
"Ipilimumab in the Treatment of Metastatic Melanoma: Proof of Principle for Checkpoint Blockade"

3:55-4:30 GLENN DRANOFF, Dana-Farber Cancer Institute, Boston, Massachusetts

"Mechanisms of Protective Tumor Immunity"


4:40-5:40 RECEPTION (refreshments provided)